Remodelling of whole-body lipid metabolism and a diabetic-like phenotype caused by loss of CDK1 and hepatocyte division

  1. Jin Rong Ow
  2. Matias J Cadez
  3. Gözde Zafer
  4. Juat Chin Foo
  5. Hong Yu Li
  6. Soumita Ghosh
  7. Heike Wollmann
  8. Amaury Cazenave-Gassiot
  9. Chee Bing Ong
  10. Markus R Wenk
  11. Weiping Han
  12. Hyungwon Choi
  13. Philipp Kaldis  Is a corresponding author
  1. Institute of Molecular and Cell Biology (IMCB), A*STAR (Agency for Science, Technology and Research), Singapore
  2. National University of Singapore (NUS), Singapore
  3. Singapore Bioimaging Consortium, Singapore
  4. Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
  5. Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore, Singapore
  6. National University of Singapore NUS), Singapore
  7. Lund University, Sweden

Abstract

Cell cycle progression and lipid metabolism are well-coordinated processes required for proper cell proliferation. In liver diseases that arise from dysregulated lipid metabolism, proliferation is diminished. To study the outcome of CDK1 loss and blocked hepatocyte proliferation on lipid metabolism and the consequent impact on whole-body physiology, we performed lipidomics, metabolomics, and RNA-seq analyses on a mouse model. We observed reduced triacylglycerides in liver of young mice, caused by oxidative stress that activated FOXO1 to promote expression of ATGL. Additionally, we discovered that hepatocytes displayed malfunctioning b-oxidation, reflected by increased acylcarnitines and reduced b-hydroxybutyrate. This led to elevated plasma free fatty acids, which were transported to the adipose tissue for storage and triggered greater insulin secretion. Upon aging, chronic hyperinsulinemia resulted in insulin resistance and hepatic steatosis through activation of LXR. Here we demonstrate that loss of hepatocyte proliferation is not only an outcome but possibly causative for liver pathology.

Data availability

Raw sequencing data is available at NCBI GEO under accession number GSE159498.

The following data sets were generated

Article and author information

Author details

  1. Jin Rong Ow

    Institute of Molecular and Cell Biology (IMCB), A*STAR (Agency for Science, Technology and Research), Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7468-691X
  2. Matias J Cadez

    Institute of Molecular and Cell Biology (IMCB), A*STAR (Agency for Science, Technology and Research), Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  3. Gözde Zafer

    Institute of Molecular and Cell Biology (IMCB), A*STAR (Agency for Science, Technology and Research), Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  4. Juat Chin Foo

    Biochemistry, National University of Singapore (NUS), Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  5. Hong Yu Li

    Singapore Bioimaging Consortium, Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  6. Soumita Ghosh

    Medicine, National University of Singapore (NUS), Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  7. Heike Wollmann

    Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  8. Amaury Cazenave-Gassiot

    Biochemistry, National University of Singapore (NUS), Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  9. Chee Bing Ong

    Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore, Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  10. Markus R Wenk

    Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore (NUS), Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  11. Weiping Han

    Institute of Molecular and Cell Biology (IMCB), A*STAR (Agency for Science, Technology and Research), Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5023-2104
  12. Hyungwon Choi

    Medicine, National University of Singapore NUS), Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6687-3088
  13. Philipp Kaldis

    Clinical Sciences, Lund University, Malmö, Sweden
    For correspondence
    philipp.kaldis@med.lu.se
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7247-7591

Funding

The work was supported in part by the Faculty of Medicine, Lund University to PK, the Biomedical Research Council, Agency for Science, Technology and Research (A*STAR) to PK and to AC-G and MRW (IAF-ICP I1901E0040); by SINGA (Singapore International Graduate Award) to GZ; by the National Medical Research Council Singapore, NMRC (NMRC/CBRG/0091/2015) to PK; by National Research Foundation Singapore grant (NRF2016-CRP001-103) to PK; by the National Medical Research Council of Singapore (NMRC-CG-M009 to H.C.); by grants from the National University of Singapore via the Life Sciences Institute to JCF; the Swedish Foundation for Strategic Research Dnr IRC15-0067; and Swedish Research Council, Strategic Research Area EXODIAB, Dnr 2009-1039. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal experiments were performed in accordance to protocols (#171268) approved by the A*STAR Institutional Animal Care and Use Committee (IACUC) based on the National Advisory Committee for Laboratory Animal Research (NACLAR) Guidelines.

Copyright

© 2020, Ow et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,445
    views
  • 370
    downloads
  • 19
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jin Rong Ow
  2. Matias J Cadez
  3. Gözde Zafer
  4. Juat Chin Foo
  5. Hong Yu Li
  6. Soumita Ghosh
  7. Heike Wollmann
  8. Amaury Cazenave-Gassiot
  9. Chee Bing Ong
  10. Markus R Wenk
  11. Weiping Han
  12. Hyungwon Choi
  13. Philipp Kaldis
(2020)
Remodelling of whole-body lipid metabolism and a diabetic-like phenotype caused by loss of CDK1 and hepatocyte division
eLife 9:e63835.
https://doi.org/10.7554/eLife.63835

Share this article

https://doi.org/10.7554/eLife.63835

Further reading

    1. Cell Biology
    2. Genetics and Genomics
    Keva Li, Nicholas Tolman ... UK Biobank Eye and Vision Consortium
    Research Article

    A glaucoma polygenic risk score (PRS) can effectively identify disease risk, but some individuals with high PRS do not develop glaucoma. Factors contributing to this resilience remain unclear. Using 4,658 glaucoma cases and 113,040 controls in a cross-sectional study of the UK Biobank, we investigated whether plasma metabolites enhanced glaucoma prediction and if a metabolomic signature of resilience in high-genetic-risk individuals existed. Logistic regression models incorporating 168 NMR-based metabolites into PRS-based glaucoma assessments were developed, with multiple comparison corrections applied. While metabolites weakly predicted glaucoma (Area Under the Curve = 0.579), they offered marginal prediction improvement in PRS-only-based models (p=0.004). We identified a metabolomic signature associated with resilience in the top glaucoma PRS decile, with elevated glycolysis-related metabolites—lactate (p=8.8E-12), pyruvate (p=1.9E-10), and citrate (p=0.02)—linked to reduced glaucoma prevalence. These metabolites combined significantly modified the PRS-glaucoma relationship (Pinteraction = 0.011). Higher total resilience metabolite levels within the highest PRS quartile corresponded to lower glaucoma prevalence (Odds Ratiohighest vs. lowest total resilience metabolite quartile=0.71, 95% Confidence Interval = 0.64–0.80). As pyruvate is a foundational metabolite linking glycolysis to tricarboxylic acid cycle metabolism and ATP generation, we pursued experimental validation for this putative resilience biomarker in a human-relevant Mus musculus glaucoma model. Dietary pyruvate mitigated elevated intraocular pressure (p=0.002) and optic nerve damage (p<0.0003) in Lmx1bV265D mice. These findings highlight the protective role of pyruvate-related metabolism against glaucoma and suggest potential avenues for therapeutic intervention.

    1. Cell Biology
    Affiong Ika Oqua, Kin Chao ... Alejandra Tomas
    Research Article

    G protein-coupled receptors (GPCRs) are integral membrane proteins which closely interact with their plasma membrane lipid microenvironment. Cholesterol is a lipid enriched at the plasma membrane with pivotal roles in the control of membrane fluidity and maintenance of membrane microarchitecture, directly impacting on GPCR stability, dynamics, and function. Cholesterol extraction from pancreatic beta cells has previously been shown to disrupt the internalisation, clustering, and cAMP responses of the glucagon-like peptide-1 receptor (GLP-1R), a class B1 GPCR with key roles in the control of blood glucose levels via the potentiation of insulin secretion in beta cells and weight reduction via the modulation of brain appetite control centres. Here, we unveil the detrimental effect of a high cholesterol diet on GLP-1R-dependent glucoregulation in vivo, and the improvement in GLP-1R function that a reduction in cholesterol synthesis using simvastatin exerts in pancreatic islets. We next identify and map sites of cholesterol high occupancy and residence time on active vs inactive GLP-1Rs using coarse-grained molecular dynamics (cgMD) simulations, followed by a screen of key residues selected from these sites and detailed analyses of the effects of mutating one of these, Val229, to alanine on GLP-1R-cholesterol interactions, plasma membrane behaviours, clustering, trafficking and signalling in INS-1 832/3 rat pancreatic beta cells and primary mouse islets, unveiling an improved insulin secretion profile for the V229A mutant receptor. This study (1) highlights the role of cholesterol in regulating GLP-1R responses in vivo; (2) provides a detailed map of GLP-1R - cholesterol binding sites in model membranes; (3) validates their functional relevance in beta cells; and (4) highlights their potential as locations for the rational design of novel allosteric modulators with the capacity to fine-tune GLP-1R responses.